Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LLY Stock Forecast 2025-2026
$791.24
Current Price
$724.72B
Market Cap
Buy 23
Hold 4
Sell 2
Wall St Analyst Ratings
Distance to LLY Price Targets
+50.4%
To High Target of $1,190.00
+22.6%
To Median Target of $970.00
-17.9%
To Low Target of $650.00
LLY Price Momentum
-2.1%
1 Week Change
+4.5%
1 Month Change
-11.2%
1 Year Change
+2.5%
Year-to-Date Change
-18.6%
From 52W High of $972.53
+16.9%
From 52W Low of $677.09
📊 TOP ANALYST CALLS
Did LLY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Eli Lilly is one of their latest high-conviction picks.
Latest LLY Stock Price Targets & Analyst Predictions
Based on our analysis of 40 Wall Street analysts, LLY has a bullish consensus with a median price target of $970.00 (ranging from $650.00 to $1,190.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $791.24, the median forecast implies a 22.6% upside. This outlook is supported by 23 Buy, 4 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Peter Verdult at Citigroup, projecting a 50.4% upside. Conversely, the most conservative target is provided by Robyn Karnauskas at Truist Securities, suggesting a 17.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LLY Analyst Ratings
23
Buy
4
Hold
2
Sell
LLY Price Target Range
Low
$650.00
Average
$970.00
High
$1,190.00
Current: $791.24
Latest LLY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LLY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 2, 2025 | UBS | Trung Huynh | Buy | Maintains | $1,050.00 |
| Apr 28, 2025 | HSBC | Rajesh Kumar | Reduce | Downgrade | $700.00 |
| Apr 22, 2025 | Cantor Fitzgerald | Carter Gould | Overweight | Initiates | $975.00 |
| Apr 14, 2025 | Guggenheim | Seamus Fernandez | Buy | Maintains | $928.00 |
| Apr 9, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $1,124.00 |
| Apr 8, 2025 | Goldman Sachs | Asad Haider | Buy | Upgrade | $888.00 |
| Mar 5, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $1,100.00 |
| Feb 3, 2025 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $1,038.00 |
| Jan 28, 2025 | Citigroup | Peter Verdult | Buy | Maintains | $1,190.00 |
| Jan 28, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $970.00 |
| Dec 10, 2024 | B of A Securities | Tim Anderson | Buy | Reinstates | $997.00 |
| Nov 15, 2024 | Wolfe Research | Alexandria Hammond | Outperform | Initiates | $1,000.00 |
| Nov 4, 2024 | Deutsche Bank | James Shin | Buy | Maintains | $1,015.00 |
| Oct 31, 2024 | Barclays | Carter Gould | Overweight | Maintains | $975.00 |
| Oct 31, 2024 | B of A Securities | Geoff Meacham | Buy | Maintains | $1,100.00 |
| Oct 25, 2024 | Citigroup | Peter Verdult | Buy | Maintains | $1,250.00 |
| Oct 17, 2024 | Bernstein | Outperform | Initiates | $1,100.00 | |
| Oct 10, 2024 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $1,033.00 |
| Oct 3, 2024 | Deutsche Bank | James Shin | Buy | Reiterates | $1,025.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $885.00 |
Eli Lilly and Company (LLY) Competitors
The following stocks are similar to Eli Lilly based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Eli Lilly and Company (LLY) Financial Data
Eli Lilly and Company has a market capitalization of $724.72B with a P/E ratio of 65.7x. The company generates $49.00B in trailing twelve-month revenue with a 22.7% profit margin.
Revenue growth is +45.2% quarter-over-quarter, while maintaining an operating margin of +42.5% and return on equity of +77.3%.
Valuation Metrics
Market Cap
$724.72B
Enterprise Value
$771.03B
P/E Ratio
65.7x
PEG Ratio
35.6x
Price/Sales
14.8x
Growth & Margins
Revenue Growth (YoY)
+45.2%
Gross Margin
+82.5%
Operating Margin
+42.5%
Net Margin
+22.7%
EPS Growth
+23.0%
Financial Health
Cash/Price Ratio
+0.5%
Current Ratio
1.4x
Debt/Equity
243.6x
ROE
+77.3%
ROA
+16.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Eli Lilly and Company (LLY) Business Model
About Eli Lilly and Company
What They Do
Pharmaceutical corporation focused on innovative medications.
Business Model
The company generates revenue through the discovery, development, manufacturing, and marketing of pharmaceutical products across various therapeutic areas such as oncology, immunology, neuroscience, and endocrinology. Its successful medications, particularly in diabetes care, contribute significantly to its income.
Additional Information
Founded in 1876 and headquartered in Indianapolis, Eli Lilly combines scientific innovation with a commitment to improve patient outcomes. Its strong pipeline and focus on research and development position it well for future growth and influence in the global pharmaceutical landscape.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
47,000
CEO
Mr. David A. Ricks
Country
United States
IPO Year
1972
Website
www.lilly.comEli Lilly and Company (LLY) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.
Jun 17, 2025
By Zacks Equity Research
Analyst Blog
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the preceding trading day.
Jun 16, 2025
By Zacks Equity Research
Tale of the Tape
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
Jun 16, 2025
By Ahan Chakraborty
Analyst Blog
Latest News
Quick Summary
Eli Lilly will sell higher dose versions of its weight-loss drug Zepbound on its website, LillyDirect.
Why It Matters
Eli Lilly's launch of higher dose Zepbound online could boost sales and market share, signaling growth potential and impacting stock performance positively.
Source: Reuters
Market Sentiment:
Positive
1 Growth Stock Down 9% to Buy Right Now
4 days ago
Quick Summary
Eli Lilly (LLY), a company established in the late 1800s, is recognized as a growth company, highlighting its ongoing expansion and potential for investors.
Why It Matters
Eli Lilly's classification as a growth company despite its long history signals strong innovation and potential for continued revenue expansion, making it an attractive investment opportunity.
Source: The Motley Fool
Market Sentiment:
Neutral
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
3 days ago
Quick Summary
Eli Lilly is a leader in the weight-management medicine market and may be surpassing its main competitor, Novo Nordisk, following recent clinical successes.
Why It Matters
Eli Lilly's advancements in weight-management drugs could enhance market share and revenue, positioning it favorably against competitor Novo Nordisk, impacting stock performance positively.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Eli Lilly will offer Zepbound (tirzepatide) 12.5 mg and 15 mg vials for $499/month under its Self Pay Journey Program, starting July 7. Clinical trials showed significant weight loss in participants.
Why It Matters
Eli Lilly's launch of Zepbound's higher doses at a fixed price enhances market accessibility, potentially driving sales and stock performance, especially with significant weight loss results in trials.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors should be aware that certain stocks exhibit high volatility and risk, which may lead to uncertainty and sleepless nights after purchase.
Why It Matters
High volatility in stocks indicates greater risk, which can lead to unpredictable returns and potential losses, impacting investment strategies and portfolio stability.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Eli Lilly's experimental obesity drug, eloralintide, demonstrated a 11.5% weight loss in some patients after 12 weeks in an early-stage study, according to Cantor Fitzgerald.
Why It Matters
Eli Lilly's promising obesity drug results could boost sales and market share in a growing sector, potentially driving stock prices higher and attracting investor interest.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About LLY Stock
What is Eli Lilly and Company's (LLY) stock forecast for 2025?
Based on our analysis of 40 Wall Street analysts, Eli Lilly and Company (LLY) has a median price target of $970.00. The highest price target is $1,190.00 and the lowest is $650.00.
Is LLY stock a good investment in 2025?
According to current analyst ratings, LLY has 23 Buy ratings, 4 Hold ratings, and 2 Sell ratings. The stock is currently trading at $791.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LLY stock?
Wall Street analysts predict LLY stock could reach $970.00 in the next 12 months. This represents a 22.6% increase from the current price of $791.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Eli Lilly and Company's business model?
The company generates revenue through the discovery, development, manufacturing, and marketing of pharmaceutical products across various therapeutic areas such as oncology, immunology, neuroscience, and endocrinology. Its successful medications, particularly in diabetes care, contribute significantly to its income.
What is the highest forecasted price for LLY Eli Lilly and Company?
The highest price target for LLY is $1,190.00 from Peter Verdult at Citigroup, which represents a 50.4% increase from the current price of $791.24.
What is the lowest forecasted price for LLY Eli Lilly and Company?
The lowest price target for LLY is $650.00 from Robyn Karnauskas at Truist Securities, which represents a -17.9% decrease from the current price of $791.24.
What is the overall LLY consensus from analysts for Eli Lilly and Company?
The overall analyst consensus for LLY is bullish. Out of 40 Wall Street analysts, 23 rate it as Buy, 4 as Hold, and 2 as Sell, with a median price target of $970.00.
How accurate are LLY stock price projections?
Stock price projections, including those for Eli Lilly and Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 18, 2025 3:31 AM UTC